Company intelligence / Profile preview

PeproMene Bio, Inc.

Irvine, California, United Statespepromenebio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

PeproMene Bio’s lead program PMB-CT01 (BAFFR-CAR T cells) has shown promising early clinical results in phase 1 studies. All treated patients with non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia demonstrated durable responses; notably, some had relapsed after CD19 CAR-T therapy or were CD19-negative. The company recently secured an $11 million investment to expand its follicular lymphoma trial cohort

Therapeutic areas: OncologyImmunology
Modalities: CAR T cellsBispecific T Cell EngagersCAR NK cells
Industry: Biotech

Drug pipeline

7 assets

PMB-CT01

6 more assets in the full pipeline.

Partnerships

Institute for Follicular Lymphoma Innovation ($11 million investment partnership)licensed intellectual property from City of Hope National Medical Center.

Beyond the preview

Go deeper on PeproMene Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeproMene Bio, Inc..